Latest Updates on VDPHL01 (April 2026)
Update (Apr 27, 2026): Veradermics announced positive topline results from Phase 2/3 Study ‘302’. VDPHL01 met all primary and key secondary endpoints: patients on the once-daily dose gained +30.3 hairs/cm² vs. +7.3 for placebo; 79–86% of patients reported improvement in hair coverage. Statistically significant hair growth was observed as early as Month 2. No cardiac adverse events were reported. Veradermics shares rose 48% on the announcement. Source: Business Wire. Full analysis: see our breakdown →
Update (Feb 9, 2026): Veradermics announced completion of enrollment in its second pivotal Phase 3 trial (‘304’ study) for male pattern hair loss. This marks the completion of enrollment across all male Phase 3 studies, with approximately 1,000 male patients enrolled across studies. Topline data from the ‘302’ trial is anticipated in H1 2026; ‘304’ confirmatory study topline data expected H2 2026. Source: Business Wire.
Update (Oct 16, 2025): Veradermics announced an oversubscribed USD 150M Series C to advance VDPHL01 through multiple Phase 3 trials. Official press release: Veradermics.
As of February 2026, the Phase 2/3 (‘302’) clinical trial for VDPHL01 is ongoing with primary completion scheduled for July 1, 2026 (NCT06724614). The drug is not approved and is not available for purchase.
Official milestones and any status changes are posted in the trial registry: ClinicalTrials.gov (NCT06724614).
What is VDPHL01?
VDPHL01 is an innovative oral drug developed by Veradermics. Unlike traditional treatments, it does not affect the hormonal system, reducing the likelihood of side effects such as decreased libido and erectile dysfunction, which are common among patients taking finasteride.
Scientists emphasize that VDPHL01 works at the molecular level, protecting hair follicles from the effects of DHT without altering hormone levels in the body. This makes it a promising option for men who experience discomfort with current treatment methods.
How Does VDPHL01 Work?
The exact mechanism of VDPHL01 remains undisclosed, but it is known to improve microcirculation in the scalp and protect hair follicles from miniaturization. Studies suggest that the drug activates specific signaling pathways in scalp cells, promoting their recovery and hair growth.
Preliminary clinical trials show that VDPHL01 stimulates new hair growth within two months of treatment initiation. Notably, there are no significant side effects commonly associated with hormonal treatments. If the results hold, VDPHL01 will be the first AGA treatment of its kind that does not interfere with the endocrine system.
Clinical Trials of VDPHL01
- Duration: 12 months.
- Visit frequency: Participants undergo evaluations every 4 weeks.
- Measured parameters: Hair growth rate, hair density, and side effects.
- Expected results: Significant hair improvement in most participants.
Update: Study ‘302’ results are now in. VDPHL01 achieved +30.3 to +33.0 hairs/cm² versus +7.3 for placebo, with 79–86% of patients reporting improvement — and statistically significant results as early as Month 2. A second confirmatory Phase 3 trial (Study ‘304’) is ongoing, with topline data expected H2 2026.
Availability / Release timeline
As of April 2026, Phase 2/3 Study ‘302’ has reported positive topline results. A second pivotal male trial (Study ‘304’, 536 patients) is fully enrolled with results expected H2 2026. A female pattern hair loss trial (Study ‘306’) is actively recruiting.
If Study ‘304’ confirms the Study ‘302’ findings, Veradermics plans to file an NDA with the FDA in early 2027, with potential approval in late 2027 or early 2028. The drug is not yet approved and is not available for purchase. See ClinicalTrials.gov.
Where to Buy VDPHL01
Once approved, VDPHL01 will be available through official medical online pharmacies and licensed distributors. To avoid counterfeit products, purchase VDPHL01 only from verified Veradermics partners.
Comparison of VDPHL01 with Existing Treatments
- Finasteride (Propecia): Blocks the enzyme 5-alpha reductase, preventing the conversion of testosterone into DHT. Stops hair loss in 85% of men, promotes new growth in 65%. Side effects include reduced libido, erectile dysfunction, and depression.
- Dutasteride (Avodart): More potent than finasteride, blocking both Type I & II 5-alpha reductase. Superior in hair regrowth but with stronger side effects.
- Minoxidil (Rogaine): Expands scalp blood vessels, increasing blood flow to follicles. Effective in 40–60% of users but may cause scalp irritation and headaches.
Expert Opinions
“If VDPHL01 truly works as the preliminary data suggests, it will be a breakthrough in AGA treatment. The lack of hormonal impact makes it attractive to millions of men who fear the side effects of traditional treatments.”
– Dr. Mark Reynolds, leading researcher in trichology.
Popular Search Queries for VDPHL01
- “VDPHL01 release date”
- “Where to buy VDPHL01”
- “VDPHL01 price”
- “VDPHL01 clinical trial reviews”
- “VDPHL01 official website”
- “When will VDPHL01 be available for purchase?”